ClinicalTrials.gg

Program

serplulimab

Also written as “HLX10”, “Serplulimab + chemotherapy (carboplatin-etoposide)” and “HLX10+chemo”.

Its studies are mostly in Small Cell Lung Carcinoma · Colorectal Neoplasms · Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms, led by 3 companies.

Furthest: phase 3, since May 6, 201927 company-led studies, 13 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma2512 open or runningphase 3since May 6, 2019Nov 19, 2018none ahead
Guangzhou FineImmune Biotechnology11 open or runningphase 1since Mar 4, 2024Mar 4, 2024none ahead
Henlix10 open or runningphase 1since Mar 11, 2018Mar 11, 2018none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 13 studies since Mar 11, 2018.

  1. Mar 17, 2021Phase 3 study in Uterine Cervical NeoplasmsFosun Pharma · NCT04806945 · China
  2. Jul 20, 2021Phase 2 study in Squamous Non-small-cell Lung CancerFosun Pharma · NCT04976647 · 156 enrolled · China
  3. Jan 22, 2022Phase 2 study in ESCC or Esophageal Adenosquamous CarcinomaFosun Pharma · NCT05221658 · 60 planned · China
  4. Feb 16, 2022Phase 2 study in Stomach NeoplasmsFosun Pharma · NCT05246982 · 40 enrolled · China
  5. Apr 25, 2022Phase 3 study in Small Cell Lung CarcinomaFosun Pharma · NCT05353257 · 511 enrolled · United States, Austria, China and more
  6. Apr 26, 2022Phase 2 study in Small Cell Lung CarcinomaFosun Pharma · NCT05354700 · 20 enrolled · China
  7. May 23, 2022Phase 1 study in Adult Solid TumorFosun Pharma · NCT05400265 · 9 enrolled · China
  8. Jun 29, 2022Phase 1 study in Solid Tumor, AdultFosun Pharma · NCT05442996 · 30 planned
  9. Jul 6, 2022Phase 1 study in Advanced or Metastatic Solid TumorsFosun Pharma · NCT05483530 · 20 enrolled · Australia
  10. Jul 11, 2022Phase 2 study in Extensive Stage Small Cell Lung CancerFosun Pharma · NCT05468489 · 200 enrolled · United States
  11. Oct 14, 2022Phase 2 study in Colorectal Cancer MetastaticFosun Pharma · NCT05584137 · 2 enrolled · China
  12. Nov 15, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungFosun Pharma · NCT05641493 · 49 planned · China
  13. Mar 4, 2024Guangzhou FineImmune Biotechnology's first study: phase 1 study in Drug-Related Side Effects and Adverse ReactionsNew to Guangzhou FineImmune BiotechnologyGuangzhou FineImmune Biotechnology · NCT06302062 · 23 planned · China
  14. Jan 22, 2025Phase 2 study in SCLC, Extensive StageFosun Pharma · NCT06812260 · 26 enrolled · Japan

TargetBeta

PDCD1 →read by rule
“A humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06812260SCLC, Extensive Stage · Japan2Active, not recruitingFosun PharmaOct 22, 202626
NCT06302062Drug-Related Side Effects and Adverse Reactions · China1RecruitingGuangzhou FineImmune BiotechnologyDec 30, 202523
NCT05641493Carcinoma, Non-Small-Cell Lung · China2RecruitingFosun PharmaMar 4, 202549
NCT05584137Colorectal Cancer Metastatic · China2TerminatedFosun PharmaDec 31, 20232
NCT05468489Extensive Stage Small Cell Lung Cancer · United States2Active, not recruitingFosun PharmaFeb 28, 2026200
NCT05483530Advanced or Metastatic Solid Tumors · Australia1Active, not recruitingFosun PharmaDec 202420
NCT05442996Solid Tumor, Adult1Not yet recruitingFosun PharmaApr 22, 202430
NCT05400265Adult Solid Tumor · China1CompletedFosun PharmaAug 31, 20239
NCT05354700Small Cell Lung Carcinoma · China2UNKNOWNFosun PharmaMar 29, 202420
NCT05353257Small Cell Lung Carcinoma · United States, Austria, China and more3Active, not recruitingFosun PharmaJun 30, 2026511
NCT05246982Stomach Neoplasms · China2UNKNOWNFosun PharmaDec 20, 202340
NCT05221658ESCC or Esophageal Adenosquamous Carcinoma · China2RecruitingFosun PharmaJun 30, 202460
NCT04976647Squamous Non-small-cell Lung Cancer · China2UNKNOWNFosun PharmaJan 30, 2023156
NCT04806945Uterine Cervical Neoplasms · China3WithdrawnFosun PharmaFeb 15, 20240
NCT04547166Colorectal Neoplasms · China, Japan3RecruitingFosun PharmaSep 24, 2025568
NCT04465734Carcinoma, Hepatocellular · China3WithdrawnFosun PharmaOct 15, 20230
NCT04301739Triple Negative Breast Neoplasms3Not yet recruitingFosun PharmaSep 7, 2022522
NCT04150575Uterine Cervical Neoplasms · China2UNKNOWNFosun PharmaJun 15, 202221
NCT04139135Stomach Neoplasms · China3UNKNOWNFosun PharmaOct 2023642
NCT04063163Small Cell Lung Carcinoma · Georgia, Poland, Russia and more3CompletedFosun PharmaMay 7, 2024585
NCT04033354Neoplasm Metastasis · United States, China, Georgia and more3Active, not recruitingFosun PharmaDec 30, 2023537
NCT03973112Carcinoma, Hepatocellular · China2UNKNOWNFosun PharmaJun 15, 2022123
NCT03958890Esophageal Squamous Cell Carcinoma · China3UNKNOWNFosun PharmaApr 30, 2023489
NCT03952403Carcinoma · China3Active, not recruitingFosun PharmaOct 1, 2023643
NCT03941574MSI-H Solid Malignant Tumor · China2RecruitingFosun PharmaMay 30, 2024108
NCT03757936Solid Tumor · China1UNKNOWNFosun PharmaSep 27, 201930
NCT03468751Neoplasm Metastasis · Taiwan1UNKNOWNHenlixJun 30, 202030

How it is read

Names in the registry

  • “HLX10”, 15 entries
  • “Serplulimab + chemotherapy (carboplatin-etoposide)”, 1 entry
  • “HLX10+chemo”, 1 entry
  • “Serplulimab Injection”, 1 entry
  • “HLX60 combined with HLX10”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.